%0 Journal Article
%T The ERAD Inhibitor Eeyarestatin I Is a Bifunctional Compound with a Membrane-Binding Domain and a p97/VCP Inhibitory Group
%A Qiuyan Wang
%A Bidhan A. Shinkre
%A Jin-gu Lee
%A Marc A. Weniger
%A Yanfen Liu
%A Weiping Chen
%A Adrian Wiestner
%A William C. Trenkle
%A Yihong Ye
%J PLOS ONE
%D 2012
%I Public Library of Science (PLoS)
%R 10.1371/journal.pone.0015479
%X Protein homeostasis in the endoplasmic reticulum (ER) has recently emerged as a therapeutic target for cancer treatment. Disruption of ER homeostasis results in ER stress, which is a major cause of cell death in cells exposed to the proteasome inhibitor Bortezomib, an anti-cancer drug approved for treatment of multiple myeloma and Mantle cell lymphoma. We recently reported that the ERAD inhibitor Eeyarestatin I (EerI) also disturbs ER homeostasis and has anti-cancer activities resembling that of Bortezomib.
%U http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0015479